What this sector typically needs
Financial modelling and advisory for care operators, healthcare infrastructure and life sciences businesses operating within regulated frameworks.
Healthcare financial work must integrate clinical capacity, regulatory constraints, NHS tariff structures, private pay dynamics and workforce economics inside a single framework. Treating any one of these as a side calculation tends to produce models that fall over under scrutiny.
Institutional capital deploying into the sector requires analysis that handles bed-day economics, occupancy and acuity sensitivity, and the financial consequences of regulatory inspection outcomes. The analytical pack has to address the questions an investment committee will actually ask before signing.
Life sciences clients have a different problem set. Pipeline assumptions need to connect coherently to market access pathways, reimbursement positioning and pricing under each route to launch. Commercial modelling here is closer to scenario architecture than to forecasting.
How we work in healthcare and life sciences
Engagements often begin around a defined transaction (a fundraise, an acquisition, a refinancing) and evolve into a retained advisory relationship once the model and reporting cadence are established. We are comfortable holding both ends of that arc.
The deliverable pack is structured to serve three audiences in parallel: clinical leadership, institutional investors, and (where relevant) regulators. That shapes how we lay out the assumption schedules, scenario layers and the executive narrative; one document, three viewpoints, internally consistent.
We distinguish carefully between financial modelling and clinical advice. The model carries the numbers; clinical leadership carries the clinical view. Our role is to make sure the financial picture reflects the operational reality with which clinicians are working.
Top services for healthcare and life sciences
The three modelling lines most engagements in this sector start with.
Financial Modelling and Forecasting
Integrated three-statement models with bed-day economics, occupancy sensitivity and tariff-versus-private-pay revenue layers built in from the start.
Investment and Commercial Analysis
Appraisal, capital structure and due diligence for healthcare acquisitions and fundraises, with explicit treatment of regulatory inspection risk in the downside case.
Strategic Financial Advisory
Retained advisory for boards and management teams on expansion, FP&A design and post-transaction integration, alongside clinical and operational leadership.
Sector-specific considerations
Regulatory inspection risk has material financial consequences and should be visible in the scenario layer, not hidden in a paragraph of the report. We model it as a distinct downside path with explicit revenue and cost impacts.
NHS tariff and private pay dynamics behave differently and require separate revenue mechanics. Blending them into a single average tends to obscure the question the investor or board is actually asking.
Life sciences pipeline assumptions must be evidenced against comparable launches, regulatory timelines and access pathways rather than asserted from internal optimism. We are willing to argue this point in writing.
We hold a firm line between financial modelling and clinical advice. Where a question is clinical in nature, we say so, and we expect clinical leadership to carry it.
Sanitised. Sector-coded. No client identification.
An engagement in Healthcare and Life Sciences
A care group with a multi-site operating footprint was preparing for an institutional fundraise to support a significant expansion programme. The question for the board was whether the group could present an integrated financial picture that connected occupancy, acuity mix and tariff-versus-private-pay revenue to the proposed expansion capital, in a form an institutional investor would interrogate without reservation.
We built an integrated three-statement model with separate revenue mechanics for NHS-funded and privately funded bed-days, an occupancy and acuity sensitivity layer, and a distinct regulatory inspection scenario carrying its own cost and revenue effects. The model was reviewed by the group's clinical leadership, by the management team, and by the incoming investor's commercial due diligence team. The fundraise proceeded and the advisory relationship was subsequently retained for the post-investment reporting cycle.
The distinctive feature was modelling regulatory inspection risk as a discrete scenario rather than a rate adjustment. A notional uplift to operating costs would have shown a smoother downside; modelling an inspection event explicitly (occupancy step-down, remediation cost, recovery profile) gave the board and the investor a credible picture of what a bad year looked like, and let them size the capital buffer to that path rather than to an average.
When this sector needs non-financial advisory
GIVE Consultancy, one call away
Sector engagements often surface questions that sit outside the analytical perimeter: regulatory exposure, internal communications, organisational capacity. Where that happens, GIVE Consultancy Limited, the second firm in the GIVE Network, is available under the same confidentiality regime. Both firms donate ten per cent of annual profits to the GIVE Foundation, the network's charitable entity. The arrangement is structural rather than commercial: it reflects how the firms were set up, not a referral incentive. Clients are introduced only on request, and only where the adjacent work is required.
Visit GIVE Consultancy (opens in a new tab)
GIVE Foundation receives ten per cent of profits from every engagement. See the giving model (opens in a new tab).
Confidentiality
The organisations that engage us ask not to be named, and we give that undertaking to every client without exception. Past work on this page is described by what was analysed and what was delivered, never by who commissioned it. The same discretion applies prospectively: any engagement with you would be held to the same standard.
Discuss a healthcare and life sciences engagement
A 30-minute introductory call, in confidence. We will tell you if your project fits this practice.